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XenopusMutations in rfx6 were recently associated with Mitchell–Riley syndrome, which involves neonatal diabetes,
and other digestive system defects. To better deﬁne the function of Rfx6 in early endoderm development we
cloned the Xenopus homologue. Expression of rfx6 begins early, showing broad expression throughout the
anterior endoderm; at later stages rfx6 expression becomes restricted to the endocrine cells of the gut and
pancreas. Morpholino knockdown of rfx6 caused a loss of pancreas marker expression, as well as other
abnormalities. Co-injection of exogenous wild-type rfx6 rescued the morpholino phenotype in Xenopus
tadpoles, whereas attempts to rescue the loss-of-function phenotype using mutant rfx6 based on Mitchell–
Riley patients were unsuccessful. To better deﬁne the pleiotropic effects, we performedmicroarray analyses of
gene expression in knockdown foregut tissue. In addition to pancreatic defects, the microarray analyses
revealed downregulation of lung, stomach and heart markers and an upregulation of kidney markers. We
veriﬁed these results using RT-PCR and in situ hybridization. Based on the different rfx6 expression patterns
and our functional analyses, we propose that rfx6 has both early and late functions. In early development Rfx6
plays a broad role, being essential for development of most anterior endodermal organs. At later stages
however, Rfx6 function is restricted to endocrine cells.Organogenesis, Institut de
Ouest, Montreal, QC H2V4K1,
, zeina.jarikji@ircm.qc.ca
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Neonatal diabetes is a rare presentation of diabetes mellitus (DM)
that affects patients during the ﬁrst 6 months of life. There are two
predominant forms of neonatal diabetes, permanent (PNDM) and
transient (TNDM). TNDM manifests early in life as insulin-dependent
diabetes which goes into remission for several years; patients then
often develop type 2 diabetes (Polak and Cave, 2007; Polak and Shield,
2004; von Muhlendahl and Herkenhoff, 1995). Approximately 68% of
TNDM cases are caused by abnormalities at chromosome 6q24, with
ZAC1 as the most likely candidate gene in this region (Arima et al.,
2001; Gardner et al., 2000; Kamiya et al., 2000). Almost 25% of the
remaining cases are caused by mutations in the genes KCNJ11 and
ABCC8, which encode subunits of the β-cell potassium channels
(Aguilar-Bryan and Bryan, 2008).
In contrast to TNDM, PNDM has no remission phase and patients
remain insulin-dependent. The etiology of PNDM is only known in
approximately half the cases (Hamilton-Shield, 2007). PNDM can
typically be divided into three subgroups: disease caused by abnormalpancreas development, disease caused by reduced β-cell mass, and
disease caused by β-cell dysfunction. Where PNDM is associated with
abnormal pancreas development, mutations were identiﬁed in PTF1A
(Sellick et al., 2004), PDX1 (Nicolino et al., 2010; Schwitzgebel et al.,
2003; Stoffers et al., 1997), HNF1β (Yorifuji et al., 2004) and GLIS3
(Senee et al., 2006). Genes associated with decreased β-cell mass are
EIF2AK3 (Delepine et al., 2000; Rubio-Cabezas et al., 2009b; Senee et
al., 2004), insulin (Edghill et al., 2008; Polak et al., 2008; Stoy et al.,
2007) and FOXP3 (Rubio-Cabezas et al., 2009a; Wildin et al., 2001).
Genes associated with β-cell dysfunction in PNDM are glucokinase
(Njolstad et al., 2003, 2001; Porter et al., 2005), KCNJ11 (Craig et al.,
2009; Gloyn et al., 2004; Shimomura et al., 2010) and ABCC8 (Babenko
et al., 2006; Ellard et al., 2007). However, the list of implicated genes is
incomplete as the genetic basis of many PNDM cases has yet to be
deﬁned.
Mitchell–Riley is a recently described neonatal diabetes syndrome
in which patients have severe neonatal diabetes and hypoplastic
pancreas accompanied by duodenal or jejunal atresia and a small or
absent gall bladder (Mitchell et al., 2004). Homozygosity mapping
identiﬁed chromosomal regions linked to Mitchell–Riley syndrome,
and sequencing candidate genes in these regions identiﬁed regulatory
factor X 6 (rfx6) (Smith et al., 2010). Five distinct mutations in the
coding sequence of Rfx6 were identiﬁed in six patients; four were
homozygous and one was a compound heterozygote. Of the four
homozygous mutations two were predicted to cause truncations, one
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exon 7. The other two homozygous mutations were mis-sense
mutations, an R181Q in the DNA-binding domain (DBD) and an
S217P between the DBD and the dimerization domain. The hetero-
zygous mutation, which consisted of two different mutations in rfx6
each on a different parental chromosome, consisted of a donor site-
loss in intron 6 on one chromosome and a disruption of the intron 1
acceptor site on the other (Smith et al., 2010). Although it is likely that
all of these mutations have a deleterious effect on pancreas
development by way of producing a defective Rfx6 protein, there is
no in vivo data to support this assumption.
The RFX family of transcription factors consists of 7 members
(Aftab et al., 2008), all of which contain the winged-helix RFX DNA-
binding domain; most also contain a dimerization domain enabling
both hetero- and homodimeric interaction (Garvie et al., 2007;
Horvath et al., 2004; Jabrane-Ferrat et al., 2002; Purvis et al., 2010;
Wolfe et al., 2008). RFX family members are known to regulate
various processes including spermatogenesis (Horvath et al., 2009,
2004; Kistler et al., 2009; Wolfe et al., 2006, 2008), MHCII regulation
(Garvie et al., 2007; Jabrane-Ferrat et al., 2002; Krawczyk et al., 2005;
Nekrep et al., 2002; Niesen et al., 2009; Rousseau et al., 2004; Seguin-
Estevez et al., 2009), and ciliogenesis (Ait-Lounis et al., 2007; Ashique
et al., 2009; El Zein et al., 2009). The only RFX genes associated with
pancreas development to date are rfx6 and rfx3, which have been
shown to be required for appropriate β-cell formation and function
(Ait-Lounis et al., 2007, 2010; Smith et al., 2010; Soyer et al., 2010).
Recent studies have shown that rfx6 is required for pancreas
development in mouse and zebraﬁsh, though substantial interspecies
differences have been identiﬁed (Smith et al., 2010; Soyer et al., 2010).
Inboth species rfx6 is expressed in twowaves, oneearly indevelopment,
before the expression of early pancreatic transcription factors such as
pdx1 and ptf1a, and the second during endocrine cell developmentwith
expression continuing through to adulthood. Loss-of-function studies
have demonstrated that rfx6 is required for development and
maturation of endocrine cells in both mice and zebraﬁsh, although
with functional differences between the two species. In mice rfx6 is
expressed broadly throughout the endoderm, whereas zebraﬁsh rfx6 is
exclusively expressed in the pancreas. Another substantial difference is
that the zebraﬁsh rfx6 knockdown led to only a small decrease in insulin
expression and a dramatic decrease in expression of glucagon,
somatostatin and ghrelin, whereas marker gene expression for all
endocrine cell types, including insulin, was dramatically reduced in
the mouse loss-of-function. Although all of these results demonstrate
that rfx6 has an important role in endocrine cell development, the
differences highlight the need for further studies of Rfx6.
To further deﬁne the role(s) of rfx6 in endoderm development we
cloned the Xenopus laevis rfx6 homologue. We show that Xenopus rfx6
is initially expressed broadly in the anterior endoderm early in
development (NF15), and that expression is later localized to the
endocrine cells of the gut and pancreas. Morpholino-induced
knockdown of rfx6 in Xenopus embryos induces a loss of pancreas
marker gene expression. This morpholino phenotype can be rescued
by co-injection of wild-type rfx6mRNA. However, functional analyses
of three mutated rfx6 mRNAs identiﬁed in Mitchell–Riley syndrome
demonstrate that these mutants cannot rescue the morpholino
phenotype. Microarray analyses of the loss-of-function (LOF) tissue
at various developmental stages conﬁrmed the loss of pancreatic
marker gene expression and revealed downregulation of genes
expressed in other endoderm-derived organs in the anterior foregut
–particularly stomach and lungs. Heart marker expression was also
reduced, while there was an upregulation in kidney marker
expression. These results demonstrate that Rfx6 is essential for
pancreas development in Xenopus and is implicated in normal
development of other foregut organs; and that mutations identiﬁed
in patients with Mitchell–Riley syndrome have a similar phenotype to
null mutants, and thus are likely to cause the syndrome.Materials and methods
Cloning of Xenopus laevis rfx6
We initially identiﬁed the Xenopus tropicalis genome sequence for
Rfx6 based on synteny mapping. Subsequently, we identiﬁed a partial
Xenopus laevis clone (XL055a12) that contained the 3'end of the
cDNA. The 3' end of rfx6was cloned using cDNA from wild-type NF35
embryos, and primers 1200 for 5'-AGGCTAGTAAACAAAATGG-3' and
revUTR 5'-ACGTTTCCATAGGAGGTAGA-3'. The 5' end of X. laevis Rfx6
was then cloned using 5'RACE with the following primers: RFXDC1-
400rev 5'-CTCACTCTTCAACTTGCTAC-3' and RFXDC1-200rev 5'-GAG-
CATAGAGTATGCATCGA-3'. The entire ORF of X. laevis Rfx6 was then
cloned by PCR using the following primers RFXDC1-afor 5'-
GGATGGTTGCATGGGCATT-3' and RFXDC1-stoprev 5'-GGATGGTTG-
CATGGGCATT-3' fromNF41whole gut cDNA using the LongRange PCR
kit (Qiagen). The PCR product was cloned into pCS2+ and veriﬁed by
sequencing. ThemRNA sequence of X. laevis rfx6 has been deposited in
GenBank with the accession number HQ665016.
To add a 5' FLAG-tag to Rfx6 PCR primers FLAG-RFXDC1for 5'-
AACCCGGTCGACTCCCGATTGAAAGG-3' and T3 5'-ATTAACCCTCAC-
TAAAGG-3' were used to amplify rfx6 from the Rfx6-pCS2 vector.
The PCR product was cloned into the CS107-FLAG vector. To create an
inducible Rfx6 construct, rfx6was ampliﬁed from Rfx6-pCS2 using the
primers FLAG-RFXDC1for 5'-AACCCGGTCGACTCCCGATTGAAAGG-3'
and T3 5'-ATTAACCCTCACTAAAGG-3'. The PCR product was cloned
upstream of the glucocorticoid receptor (GR) domain creating FLAG-
Rfx6-GR and veriﬁed by sequencing.
Xenopus versions of the neonatal diabetes patient mutations were
also cloned. The S217P mutant was created by introducing the
mutation and an XmaI site. The gene was ampliﬁed in two fragments
both using Rfx6-pCS2 as template. The 5' fragment was ampliﬁed
using primers SP6 5'-GATTTAGGTGACACTATAG-3' and Rfx6StoPX-
maIrev 5'-CAACTTGCTCCCGGGAAACCTTGTC-3' (the reverse primer
containing the restriction site and the mutation). The 3' fragment was
ampliﬁed using primers Rfx6StoPXmaIfwd 5'-GACAAGGTTTCCCGG-
GAGCAAGTTGA-3' and CS2T7 5'-GTAATACGACTCACTATAG-3'. The
two fragments were then ligated together into pCS2+ and the
mutation veriﬁed by sequencing, and then subcloned with a 5' FLAG-
tag. To create an inducible S217P clone the GR domain was ampliﬁed
from the Rfx6-GR vector using primers RQandSPmuts_GRfor 5'-
CGTAAATCCTCAATGGCATC-3' and RQandSPmuts_GRrev2 5'-GTATCT-
TATCAGGCCTGGATCTACG-3'. This PCR product was then cloned into
the FLAG-S217P vector using EcoRV/StuI restriction enzymes giving
the inducible mutant construct FLAG-Rfx6S217P-GR. The R181Q
mutant was created by introducing the mutation and a KpnI site
into primers. The gene was ampliﬁed in two fragments, both PCR
reactions using FLAG-Rfx6 as a template. The 5' fragment was
ampliﬁed with primers SP6 5'-GATTTAGGTGACACTATAG-3' and
Rfx6R181QrevKpnI 5'-GAATGTCCTCGGGTACCAAGTTGTCTTGTCGTC-
3'. The 3' fragment was ampliﬁed with primers Rfx6R181QforKpnI
5'-CAAGAAGACTTGGTACCCGAGGACATTC-3' and CS2T7 5'-GTAATAC-
GACTCACTATAG-3'. The two fragments were cloned together into
pCS2+. To create an inducible clone the GR domain was ampliﬁed
from the Rfx6-GR vector using primers RQandSPmuts_GRfor 5'-
CGTAAATCCTCAATGGCATC-3' and RQandSPmuts_GRrev2 5'-GTATCT-
TATCAGGCCTGGATCTACG-3'. This PCR product was then cloned into
the FLAG-R181Q vector using EcoRV/StuI restriction enzymes result-
ing in the inducible mutant construct FLAG-Rfx6R181Q-GR.
Amutant truncated after Exon7was created by amplifying theﬁrst 7
exons of Rfx6 from the Rfx6-pCS2 plasmid using primers SP6 5'-
GATTTAGGTGACACTATAG-3' primer and Rfx6ENDEX7 5'-TTTCTTTGGA-
TATGCCCCCT-3'. The PCR product was ligated into pCS2+, and then
subcloned with a 5' FLAG-tag and veriﬁed by sequencing. To create an
inducible clone the GR domain was ampliﬁed from Rfx6-GR using
primers endEX7_GRfor 5'-CGAGTACCGTACGTACGAGAGATCT-3' and
Fig. 1. Rfx6 expression in the endoderm and isolated gut tissue. (A) Sagittal bisection of
an NF15 embryo showing an anteriorly localized stripe of rfx6 expression. (B) Sagittal
bisection of an NF20 embryo showing rfx6 expression. (C) Transverse section through
rfx6 expressing region of NF24 embryo showing broad expression in anterior
endoderm. (D) NF28 embryo showing rfx6 expression restricted to a dorsal (arrow)
and ventral (arrowhead) patch in the anterior foregut. (E) NF40 liver and pancreas
showing rfx6 expression in the dorsal pancreas. (F) NF42 liver and pancreas showing
rfx6 expression spreading to the ventral pancreas. (G) NF46 liver and pancreas
showing rfx6 evenly expressed throughout the pancreas. (H) NF42 whole gut showing
rfx6 expression in the dorsal pancreas, stomach and intestine. (A, B, D) Anterior is left.
(A–D) Dorsal is up. (H) li, liver; p, pancreas; st, stomach. (I) RT-PCR of rfx6 in whole
tadpoles at various stages throughout development.
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was cloned into the FLAG-EX7 vector using SnaBI, resulting in the
inducible mutant construct FLAG-EX7-GR.
Probes and whole mount in situ hybridizations
The 3' end of foxA2 was cloned using cDNA from wild-type NF35
embryos and primers FoxA2for 5'-GAATCCCATGAACACGTACATGA-3'
and FoxA2rev 5'-AGAGCCCAGGTGACAAGTCC-3' designed based on
BC155932. KcnJ1 was cloned using cDNA from wild-type NF35
embryos and primers KcnJ1for 5'-TGCAGCTACCTTCTTTCTGACA-3'
and KcnJ1rev 5'-GGGCACACCTATTCCTCAAA-3' designed based on
BC059301. The sox17α and sizzled plasmids were a gift from Aaron
Zorn; all other genes were cloned previously, further details are
available on request (Horb and Horb, 2010; Horb et al., 2009, 2003;
Horb and Slack, 2002; Jarikji et al., 2009, 2007). PCR products were
cloned into pCRII (Invitrogen) and conﬁrmed by sequencing. Whole
mount in situ hybridizations were performed as described using BM
purple (Horb et al., 2003).
Antisense morpholino and mRNA injections
Antisense morpholino oligonucleotides were designed and man-
ufactured by Gene Tools LLC. Morpholinos were designed against
either the rfx6 translation start site (MO1) or the acceptor site of rfx6
intron 2 (MO2). An antisense mis-match morpholino (MM) was used
as a control, containing 5 bp mis-match to the translation start site to
disrupt binding. The sequences of the antisense morpholinos used
are: MO1 5'AATTGGCATTTCACCGGGTTCAGGC-3'; MO2 5'AGAGAG-
CATTATACCTTTCCAAATG-3'; MM 5'AATaGGgATTTgACCcGGTT-
CAcGC-3' (mis-matched base pairs in lower case). Morpholinos
were injected into the dorsal vegetal cells at the eight-cell stage.
Morpholinos were manufactured with ﬂuorescein-labeled oligonu-
cleotides and targeting was veriﬁed by observing ﬂuorescence after
dissection of whole guts from injected embryos. For functional
analysis we selected only samples for which the entire foregut was
targeted. All mRNA for microinjection was created using the Ambion
mMessage mMachine kit. To conﬁrm targeting, experimental mRNAs
were injected along with 400 pg gfp mRNA and targeting veriﬁed by
observing appropriate ﬂuorescence.
Tnt assay
The in vitro transcription and translation assay was performed
using the TNT Quick Coupled Transcription/Translation System
(Promega) following manufacturer's instructions. Rfx6 mRNA cloned
with a 3' FLAG-tag was used with the start site morpholino (MO1) to
conﬁrm inhibition of translation, and the mis-match morpholino
(MM) as a control. Western blots were performed using an anti-FLAG
antibody.
Microarray analysis
MO1 and MMwere injected into the dorsal vegetal blastomeres at
the eight-cell stage. Anterior guts were collected at NF30, NF40 and
NF44. Only samples that were targeted throughout the entire anterior
gut were dissected. Sample sets (10 guts/set) were stored in RNAlater
(Ambion); RNA extraction was performed using TRIzol (Invitrogen)
and puriﬁed using the RNeasy Micro Kit (Qiagen). RNA analysis, cDNA
preparation and hybridization were performed by Genome Québec
(McGill University, Montréal).
Microarray results were analyzed using Affymetrix Expression
Console and normalized using the Probe Logarithmic Intensity ERror
estimation (PLIER) algorithm. Differential gene expression was
analyzed using consecutive sampling with bin size of 25 (Guilbault
et al., 2006; Novak et al., 2006a, 2006b, 2002). Representativestandard deviations in each bin were calculated using non-linear
regression to determine the boundaries of probability intervals.
Candidate genes were selected as genes that lay beyond the
probability interval of 0.9 in 6 or more comparisons. The microarray
data discussed in this publication have been deposited in NCBI's Gene
Expression Omnibus (Edgar et al., 2002) and are accessible through
GEO series accession number GSE23642 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE23642).Results
Rfx6 expression in Xenopus anterior endoderm becomes restricted as
development proceeds
To identify Xenopus Rfx6 we used synteny mapping (human-
Xenopus) to identify the genomic sequence for Xenopus tropicalis Rfx6.
Using this sequence information we identiﬁed and cloned the full
length Xenopus laevis ortholog of rfx6 (see materials and methods).
The Xenopus Rfx6 protein shares 69% amino acid identity with human
Rfx6, 68% with mouse and 63% with zebraﬁsh. The Xenopus RFX
domain is identical to the human DNA-binding domain (DBD), and
only one and two amino acids different to the mouse and zebraﬁsh
DBDs, respectively. Expression pattern analysis of rfx6 revealed that it
was expressed in two distinct phases. In the ﬁrst phase, rfx6
expression was found throughout the anterior endoderm in a broad
domain from NF15 until NF34. At NF28 rfx6 expression begins to be
localized to a dorsal and ventral region of the developing endoderm
corresponding to the dorsal and ventral pancreatic buds (Fig. 1A-D).
Expression then decreases at NF34 (Fig. 1I) and is no longer detectable
by in situ at NF35 (data not shown). In the second phase, rfx6 was
expressed in a punctate fashion throughout the gut and developing
pancreas beginning at NF40, similar to that seen for other endocrine
markers (Fig. 1E–H). Early in pancreas development (NF40), Xenopus
rfx6 was expressed exclusively in the dorsal pancreas (Fig. 1E); by
NF42 punctate expression of Rfx6 was also found in the ventral
portion of the pancreas (Fig. 1F). This expression pattern is
reminiscent of that seen with other endocrine progenitor markers
such as insm1 suggesting that rfx6 is expressed in endocrine
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2009; Pearl et al., 2009).
Rfx6 is required for both anterior endoderm patterning
and pancreas development
To determine if rfx6 is required for pancreas development we
produced a knockdown phenotype using anti-sense morpholino
oligonucleotides. One morpholino was designed to the translation
start site (MO1) and a second designed to the acceptor site of intron 2
(MO2). As a control we used a 5 bp mis-match morpholino (MM)
based onMO1. The ability of MO1 to block translation was tested with
an in vitro transcription and translation assay (Fig. 2A), and RT-PCR
was utilized to conﬁrm that MO2 blocked intron splicing in vivo
(Fig. 2B, C). The morpholinos were targeted to the anterior endoderm
by injection into the two dorsal vegetal blastomeres at the eight-cell
stage. Embryos injected with 25 ng of MO1 initially developed
normally through gastrulation and neurulation with no change in
expression of the general endoderm marker sox17α or the anterior
endodermal genes hex, sizzled, foxA2 and hnf6 prior to NF20 (data not
shown). However, beginning at NF25 we observed reduced expres-
sion of hnf6 and foxa2, but normal expression of hex, sizzled and
sox17α (Fig. 2D–G, and data not shown). By NF35, expression of all
anterior endodermal markers (hnf6, pdx1 and ptf1a) were reduced
(Fig. 2H-K). To determine if differentiation of early beta cells was also
affected by the knockdown of Rfx6, we examined whether initialFig. 2. Rfx6 LOF leads to decreased expression of foregut and pancreas markers early in pa
translation. This demonstrates that MO1 prevents translation of rfx6mRNA, while the mis-m
match morpholino. (B) Diagramatic representation of RT-PCR test of MO2 efﬁciency. (C) RT-
leaving the reverse primer unable to bind resulting in no ampliﬁcation in the Rfx6 pane
demonstrated by the presence of PCR product in MO2 lane. Ef1α is a housekeeping gene
endoderm at NF25 (24/28 reduced). (F,G) FoxA2 expression is reduced in themorphant foreg
at NF35 (10/13 reduced). (J, K) Pdx1 expression is reduced in the morphant (17/19 reduced)
pancreatic buds of the morphant (n = 18). (N, O) Early insulin expression in the dorsal pan
injected with 25 ng mis-match morpholino.insulin expression was reduced. By NF35, insulin expression is readily
detected in the dorsal endoderm of MM morphants (Fig. 2N).
However, in embryos injected with Rfx6 MO1 we did not detect any
insulin expression (Fig. 2O). At later tadpole stages we also found
reduced expression of all anterior endodermal markers. Within the
pancreas, expression of the pancreatic transcription factors pdx1 and
ptf1a was almost completely abolished, as was expression of the
differentiation markers elastase and insulin (Fig. 3A–J). In addition, we
did not detect expression of any endocrine markers (glucagon,
somatostatin or neuroD) within the gastrointestinal tract (Fig. 3K–P).
These results demonstrated that loss of rfx6 had no effect on early
gastrula and neurula stages, but that rfx6 was speciﬁcally required
beginning at early tailbud stages when regional speciﬁcation of the
anterior endoderm is solidiﬁed and was also required for proper
differentiation of most of the anterior endoderm.
Rfx6 knockdown phenotype is speciﬁc to loss of rfx6 expression
Since injection of unmodiﬁed Rfx6 resulted in an early gain-of-
function phenotype, we conﬁrmed that the knockdown phenotype
was speciﬁcally related to the loss of Rfx6 with rescue experiments
using a hormone-inducible Rfx6 (Rfx6-GR). We determined that
100 pg of rfx6-GR was sufﬁcient to rescue the knockdown phenotype
produced by 40 ng of MO2. Similar results were obtained with MO1,
though the rescue was not as efﬁcient (data not shown). Speciﬁcally,
we found that Rfx6-GR could only rescue the morphant phenotypencreas development. (A) Western blot with anti-ﬂag antibody of in vitro TnT assay of
atch morpholino (MM) does not. Rfx6 mRNA, ﬂag-tagged rfx6mRNA plasmid; MM, mis-
PCR performed on wild-type (WT) and MO2-injected tadpoles. WT mRNA is processed
l. MO2 blocks mRNA processing at the intron 2 donor site (5' end of the intron) as
used as a loading control. (D, E) Hnf6 expression is reduced in the morphant foregut
ut endoderm at NF25 (17/28). (H, I)Hnf6 expression is reduced in themorphant foregut
. (L,M) Ptf1a expression is reduced in both the dorsal (arrow) and ventral (arrowhead)
creatic bud (arrow) is lost in morphant tissue (56/62 reduced). Control tadpoles were
Fig. 3. Rfx6 is required for pancreas differentiation. Whole mount in situ hybridizations of NF42 whole guts from morphant (MO1) and mis-match (control) tadpoles. (A–D)
Expression of pancreatic transcription factors pdx1 (n = 18) and ptf1a (n = 18) is almost completely abolished in morphant tissue. (E, F) Expression of acinar marker elastase is
reduced (n= 16). (G, H) Schematic illustrating organs in the whole gut. Pink, liver; red, gall bladder; blue, pancreas; yellow, stomach, duodenum and intestine. (I, J) β cell marker
insulin is reduced (72/75 reduced). (K–N) Glucagon and somatostatin, bothmarkers of endocrine cells in the pancreas and stomach are reduced (glucagon n=18, somatostatin 15/16
reduced). (O, P) NeuroD, developmental endocrine cell marker, is reduced (n = 17).
Fig. 4. Rfx6 mRNA rescues the morpholino knockdown phenotype. (A) Control whole gut stained for elastase expression (n = 9). (B, C) Whole guts from embryos injected with
40 ng MO2, elastase expression is reduced (n = 47, 6 moderate, 41 severe). (B) Moderate MO2 phenotype, (C) Severe MO2 phenotype. (D) Whole gut from embryo injected
with 40 ng MO2 and 100 pg rfx6-GR mRNA. No dexamethosone was added. Elastase expression is reduced (n = 32, 8 normal, 15 moderate, 9 severe). (E) Whole gut from
embryo injected with 40 ng MO2 and 100 pg rfx6-GR mRNA. 2 μg/mL dexamethosone was added at NF25 to activate Rfx6-GR protein. Elastase expression is restored (n = 36,
20 normal, 15 moderate, 1 severe). (F) Rescue results from all experimental whole guts. Severe phenotype refers to complete absence of elastase expression and gut
malformation; moderate phenotype refers to reduced elastase expression and some gut malformation; normal refers to whole guts with normal levels of elastase expression
and normal overall gut morphology.
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a gain-of-function phenotype. To aid analysis, phenotypes were
divided into three groups: normal, consisting of normal elastase
expression such as that seen in the controls with normal gut
morphology; moderate, with reduced elastase expression, abnormal
gut morphology and a reduced pancreas size; and severe, where
elastase expression was absent and foregut severely deformed so that
organs could not readily be distinguished (see Fig. 4 for representative
examples of each phenotype). When embryos were injected with
MO2, elastase expressionwas reduced (n=47, 6moderate, 41 severe),
while in embryos co-injected with 100 pg of rfx6-GR and induced at
NF25, elastase expressionwas partially restored (n=36, 20 normal, 15
moderate, 1 severe) (Fig. 4). In addition,we found insulin expression to
be partially restored in the Rfx6-GR treated tadpoles (data not shown).
These results demonstrate that the morpholino-injected phenotype is
speciﬁcally due to loss of Rfx6. Furthermore, the fact that Rfx6-GR
could only rescue the morphant phenotype when induced at NF25
agrees with our previous results in which we do not detect any
reduction in gene expression in the anterior endoderm until NF25.
Mutant rfx6 cannot rescue the loss-of-function phenotype thus rfx6 is a
candidate gene for neonatal diabetes
Although mutations in rfx6 have been identiﬁed in patients with
neonatal diabetes, their in vivo function was not tested (Smith et al.,
2010). We used our morpholino-induced phenotype to determine if
these mutations produced non-functional proteins, and therefore
could contribute to or cause, neonatal diabetes. We tested the abilityFig. 5. Mutant rfx6 mRNA cannot rescue the morpholino knockdown phenotype. (A) Con
injected with 40 ng MO2, elastase expression is reduced (n = 26, 4 normal, 8 moderate, 14
GR mRNA. No dexamethosone was added. Elastase expression is reduced (n = 12, 1 mod
rfx6R181Q-GR mRNA. 2 μg/mL dexamethosone was added at NF25 to activate Rfx6R181Q
severe). (E) Rescue results for three rfx6 mutants: R181Q, S217P, and EX7 (Rfx6 is trunca
and gut malformation; moderate phenotype refers to reduced elastase expression and s
expression and normal overall gut morphology. S217P−dex n = 16, 2 normal, 2 moderate
moderate, 11 severe. EX7 +dex n = 16, 1 normal, 1 moderate, 14 severe.of three of the Rfx6 mutations in the context of the rescue
experiment described above, using hormone-inducible versions for
each construct. Control whole guts showed wild-type elastase
expression (Fig. 5A, n = 17); when 40 ng MO2 was injected elastase
expression was reduced (Fig. 5B, n = 26, 4 normal, 8 moderate, 14
severe). The ﬁrst mutation we tested was the R181Q mutation, which
lies in the DNA-binding domain (DBD), and based on the structure of
DNA-bound human RFX1 DBD this residue makes direct contact with
the DNA of the X-box (Gajiwala et al., 2000). The R181Q mutant
introduces a charge reversal in a key DNA-binding residue. Co-
injection of 100 pg R181Q mRNA did not rescue the knockdown
phenotype (Fig. 5, n = 16, 3 normal, 4 moderate, 9 severe). The
second mutation tested, S217P, is located C-terminal to the DBD in an
unknown functional domain; however, proline residues can intro-
duce kinks into proteins and disrupt their structure. Co-injection of
100 pg of S217P was also unable to rescue the knockdown phenotype
(Fig. 5E, n = 16, 2 moderate, 14 severe). The third mutant construct
we tested was the exon 7 truncation mutant, which still contains the
DBD, but lacks the dimerization domain. RFX transcription factors are
known to bind as homo- or heterodimers to alter gene expression
and the expected inability of the exon 7 mutant to functionally
dimerize appears to affect the function of Rfx6 as co-injection of 100 pg
of the exon 7 mutant also did not rescue the morphant phenotype
(Fig. 5E, n=16, 1 normal, 1moderate, 14 severe). Taken together these
results show that, unlike the wild-type Rfx6, these mutant constructs
were unable to rescue the morphant phenotype, which suggests that
these speciﬁc mutations identiﬁed in Mitchell–Riley patients do have
an in vivo effect and contribute to disease progression.trol whole gut stained for elastase expression (n = 17). (B) Whole gut from embryo
severe). (C) Whole gut from embryo injected with 40 ng MO2 and 100 pg rfx6R181Q-
erate, 11 severe). (D) Whole gut from embryo injected with 40 ng MO2 and 100 pg
-GR protein. Elastase expression remains reduced (n = 16, 3 normal, 4 moderate, 9
ted after exon 7). Severe phenotype refers to complete absence of elastase expression
ome gut malformation; normal refers to whole guts with normal levels of elastase
, 14 severe. S217P +dex n = 16, 2 moderate, 14 severe. EX7−dex n = 13, 1 normal, 1
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increase in kidney tissue
To gain further insights into the Rfx6 mechanism of action we
performed a microarray on Rfx6 loss-of-function tissue at various
stages throughout development (Fig. 6A). MO1 was used to create
loss-of-function tadpoles, and MM was used to produce controls. We
analyzed gene expression in the anterior foregut of control and
morphant tadpoles at NF30, just after the pancreatic region was
speciﬁed; at NF40, just after the pancreatic buds have fused; and at
NF44, once themature cell types had differentiated. The samples were
hybridized to the Affymetrix Xenopus laevis GeneChip 2.0. Results
were analyzed using Affymetrix Expression Console and normalized
using the PLIER algorithm. Ratios of expression levels in MM samples
compared to expression in MO1 samples were calculated and gene
lists analyzed. In general, the microarray results concurred with our
phenotypic characterization showing downregulation of pancreas,
stomach, intestine, heart and lung genes, whereas results for liver
marker genes was inconclusive. Interestingly, the microarray data did
show an increase in kidney marker genes (Table 1).
To conﬁrm differential gene expression we performed RT-PCR
analysis of selected genes identiﬁed as differentially expressed in the
microarray (Fig. 6B).Wewere able to conﬁrm themicroarray data and
found that genes differentially expressed in the microarray were also
similarly differentially expressed in themorphant RT-PCRs (Fig. 6B-D).
To further verify differential gene expression we performed in situ
hybridization on control and morphant whole guts at NF42 using
probes against selected differentially expressed genes conﬁrmed by
RT-PCR (Fig. 7). Stomach markers agr2 and frp5were reduced, as was
the lung marker surfactant C, and the heart marker nkx2.5 (Fig. 7A–H).
In contrast, we found increased expression of kidney marker kcnj1,
conﬁrming the results observed in the microarray (Fig. 7I, J). Although
expression of liver marker hex seemed unaffected by the loss of rfx6,
the liver did appear smaller (Fig. 7K, L). Last, we also found that the gall
bladder was unaffected, as the gall bladder component of hnf6 andFig. 6. LOFmicroarray experiment schematic and RT-PCR veriﬁcation of selected genes. (A) Sc
with 25 ng of either Rfx6 start site morpholino (MO) or mis-match control (MM). Samples w
Xenopus laevis GeneChip 2.0. (B–D) RT-PCR veriﬁcation of selected differentially expressed
experiment showed upregulation; −, microarray experiment showed downregulation, NA
experiments, NC, the microarray experiment detected no change. Differential expression in R
match control; MO, MO1; -RT, control reaction without reverse transcriptase.sox17α expression was normal (Fig. 7M–P). Although expression of
thesemarkerswas not changed in themicroarraywe included them in
our in situ analysis because the gall bladder is often affected in
Mitchell–Riley syndrome (Mitchell et al., 2004). In conclusion, the
microarray data conﬁrmed our phenotypic characterization and
showed that rfx6 has a broader role in endoderm development than
simply endocrine cells.Discussion
Mitchell–Riley syndrome was recently described, as a neonatal
diabetes syndrome that involves abnormalities of the anterior gut as
well as diabetes (Mitchell et al., 2004). Patients with this syndrome
are typically diagnosed within the ﬁrst week of life and generally die
within their ﬁrst year of life (Smith et al., 2010). The early onset and
severity of disease suggests that in patients with Mitchell–Riley
syndrome the pancreas does not develop appropriately in utero.
Homozygosity mapping of patients and unaffected family members
indicated several chromosomal regions were potentially involved
(Smith et al., 2010). The gene coding for the transcription factor Rfx6
was located in one of these regions.
The rfx6 expression pattern was ﬁrst described in zebraﬁsh and
mice (Smith et al., 2010; Soyer et al., 2010). Rfx6 is initially expressed
broadly in the anterior endoderm early in development and becomes
more restricted as development progresses, eventually becoming
restricted to the endodermal cells of the gut and pancreas (Smith et
al., 2010; Soyer et al., 2010). There are some important differences in
rfx6 expression between the species studied. Our studies show that
Xenopus rfx6 is expressed in the pancreas, stomach and intestine but
not in the liver (Fig. 1), whereas mouse studies have shown rfx6 is
expressed throughout endoderm-derived tissues, including the liver
(Smith et al., 2010). Zebraﬁsh rfx6 expression is slightly different
again, with expression limited solely to the pancreatic region (Soyer
et al., 2010). These ﬁndings combined suggest that rfx6 has anhematic diagram of LOFmicroarray experiment. Eight-cell stage embryos were injected
ere collected at NF30, NF40 and NF44, RNA was extracted and hybridized to Affymetrix
genes from the LOF microarray analysis. (B) NF30. (C) NF40. (D) NF44. +, microarray
, this probe was not on the microarray but was shown to be downregulated in in situ
T-PCR ﬁndings are consistent with results seen in the microarray experiment. MM, mis-
Table 1
Genes differentially expressed in Rfx6 LOF microarray Genes have been sorted into
categories based on the organ in which they are expressed. Fold change is relative to
control samples, negative numbers represent downregulation in LOF tissue. NC, no
change. NA, not applicable, the gene in question is not expressed that that time point.
p b0.05.
Fold change
Unigene ID NF30 NF40 NF44
Pancreas
amy2A xl.21603 NA NA −121.10
elas xl.26506 NA −8.88 −72.36
DNase1-A xl.932 NC NC −27.66
cel xl.24591 NA −10.85 −23.57
sst xl.13593 NA +2.30 −15.00
PDI xl.80673 NA −13.94 −11.46
ctrb1 xl.77315 NA -7.02 −8.53
trypsin xl.1858 NA NC −4.94
gcg-a xl.193 NA NC −4.51
ins1-a xl.817 −2.21 −5.84 −4.03
nm-a xl.830 NA NC −2.08
Ptf1a xl.29862 NC −3.62 −3.77
scg3-A xl.15 NA NC −2.10
cela1 xl.68767 NA −8.28 NC
igf2-A xl.23623 −2.79 −5.70 NC
ctrl xl.23397 NA −4.73 NC
PP11-like xl.82301 NA −4.69 NC
hlxb9 xl.55462 NA −3.17 NC
cpa1 xl.73839 NA −2.12 NC
NeuroD xl.26304 −1.86 NC NC
Stomach
ATP4B xl.26547 NC NC −69.82
ATP4A xl.971 NC NC −33.21
tm4sf3 xl.24486 NC NC −10.26
agr2 xl.25847 NC +3.67 −6.74
Nkx6.2 xl.55860 NC −6.92 −3.98
Sfrp2 xl.15963 NC +2.16 NC
PitX1 xl.34927 +1.75 NC NC
Liver
alb-b xl.395 NC NC −18.94
adh8 xl.53979 NC −5.52 −2.24
ca6 xl.14854 NC −7.99 NC
tm4sf4 xl.53955 NC −−5.21 NC
ITIH3 xl.5040 NC −4.48 NC
fabp-a xl.21513 NC −2.97 NC
hnf4 xl.1217 +1.73 NC NC
adh6 xl.48167 NC NC +12.86
arg1 xl.1242 NC +2.16 +16.96
Intestine
villin1 xl.81110, xl.24670 NC −4.21 NC
crip1a xl.48993 NC −3.01 NC
xCad2 xl.1358 NC NC +3.08
hand1 xl.1098 NC NC +3.47
soat2 xl.53150 NC NC +6.64
gamt xl.11235 NC NC +8.31
darmin xl.76581 NC NC +8.59
Heart
MLClv xl.76359, xl.2576 NC −9.50 −5.93
MYH6 xl.50419 −5.73 −3.95 NA
tnni3 xl.935 NC −2.93 NA
tbx5 xl.529 −1.79 −2.40 NA
tnnc1 xl.2228 −3.97 −2.28 NA
tnnt2 xl.23777 −1.60 -2.10 NA
mlc1av-A xl.11969 −5.29 −2.06 NA
nkx2.5 xl.22859 −1.92 −1.73 NA
mlc2a xl.76247 −6.16 NC NA
MYH6 xl.3161 −6.14 NC NA
mybpc3 xl.2416 −1.57 NC NA
nkx2.10-A xl.623 −1.57 NC NA
camk1 xl.63784 NC +3.33 +3.81
MyHC xl.80374 NC +1.79 +3.88
Lung
SFTPC xl.55371 NA −15.60 NA
cldn18 xl.9841 NA −13.13 NA
Table 1 (continued)
Fold change
Unigene ID NF30 NF40 NF44
EST lung xl.29467 NA −2.45 NA
slc34a2 xl.5596 NA −2.09 NA
RSpo2 xl.49496 NA −1.53 NA
Kidney
tm4sf5 xl.51559 NC −2.47 NA
kcnj1 xl.29882 NC +2.69 NA
gcm-1 xl.16562 NC +3.13 NA
UCP2 xl.27125 NC +3.57 NA
FoxC1 xl.76079 −1.75 NC NA
ndrgl xl.77767 −1.62 NC NA
nphsl xl.14805 −1.59 NC NA
frzb2 xl.619 +1.71 NC NA
Hlbox1 xl.1209 +1.90 NC NA
tm6sf1 xl.2482 +2.17 NC NA
slc3a2 xl.10583 NC NC +2.34
slc7a8 xl.15844 +2.11 NC +2.81
slc43a2 xl.5041 NC NC +2.81
PitX2A xl.104 NC NC +2.86
cln6 xl.23306 NC NC +4.93
cldn4L1 xl.21063 NC NC +5.31
xPox2 xl.11968 NC +2.95 +6.18
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organs differs between animal species.
Loss of Rfx6 leads to a loss of endocrine cells in all studies to date,
however the details differ between studies. In this study we showed
that knockdown of Rfx6 leads to a loss of both endocrine and exocrine
gene expression, including a drastic reduction in insulin expression.
Similar experiments in zebraﬁsh however, show only a slight
reduction in insulin expression with a drastic decrease in expression
of marker genes for other endocrine cell types (Soyer et al., 2010). In
contrast, the mouse knockout showed that endocrine gene expression
is lost, while exocrine cell types are unaffected (Smith et al., 2010).
Our knockdown phenotype is more similar to the mouse knockout
than the zebraﬁsh knockdown, although our phenotype is more
severe than both. It is possible that in mice and zebraﬁsh other RFX
proteins have overlapping functions, decreasing the severity of the
knockout phenotype. Interestingly, the mouse knockout was created
by ablating only the ﬁrst ﬁve exons of rfx6, which removes the DNA-
binding domain while the dimerization domain coding sequence
remains intact. Consequently there is potential for a truncated C-
terminal protein to be expressed, which could hypothetically interact
with rfx6 binding partners, and explain the lack of a phenotype in
murine exocrine cells. Thus this knockout might not accurately
represent the null phenotype; a complete mouse knockout may give
rise to results similar to what we report in Xenopus. The zebraﬁsh Rfx6
knockdown study did not assess the effect on exocrine cell types, and
thus exocrine gene expression may also have been lost in that system.
In addition to the effects on pancreatic genes, our microarray analysis
of the Xenopus LOF demonstrated that stomach, lung and heart were
also lost in the Rfx6 knockdown. Other studies have not explored the
effect of loss of Rfx6 on other organs. As Rfx6 is not expressed in
tissues other than the pancreas in zebraﬁsh it is unlikely that loss of
Rfx6 would affect other tissues signiﬁcantly. In the mouse, however,
Rfx6 is expressed throughout the endoderm-derived organs yet the
only mention of effect of LOF on non-pancreatic tissues is a distension
of the gut in the knockout mouse (Smith et al., 2010). The zebraﬁsh
knockdown of Rfx6 was shown to prevent endocrine cells from
maturing, leading to an increase in endocrine progenitor cells; though
this did not appear to apply to beta cells, as insulin expression was not
greatly decreased. Neither our study nor the mouse knockout
however, showed an increase in progenitor cells. This suggests that
the Xenopus knockdown phenotype is more similar to the mouse
knockout than to the zebraﬁsh knockdown.
Fig. 7. In situ hybridization conﬁrms differential expression of organ marker genes for stomach, lung, heart and kidney in LOF microarray. (A, B) Isolated whole gut NF42 showing
expression of stomach marker agr2 almost entirely abolished in morphant tissue (n= 23). (C, D) Expression of stomach marker frp5was reduced (n= 18). (E–J) Whole tadpoles at
NF42 with ventral skin removed for in situ hybridization. (E, F) Lungmarker surfactant C (SurfC) is decreased in morphant tissue, closed arrows (10/14 reduced). (G,H) Heart marker
nkx2.5 is decreased in morphant tissue, open arrow (8/14 reduced). (I, J) Kidney marker kcnJ1 is increased in morphant tissue, arrowhead (8/11 increased). (K,L) Expression of liver
marker hex is unaffected by rfx6 knockdown (n=32). (M,N) Expression of gall bladder and duodenummarker hnf6 is reduced in duodenum but not gall bladder (17/18). (O, P) Gall
bladder marker sox17α was not reduced (18/20 showed normal expression).
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exogenous wild-type rfx6 we were able to verify that our rfx6
knockdown was speciﬁcally caused by a loss of rfx6. We used a
dexamethosone-inducible mRNA construct and activated the protein
at NF25, before pancreatic speciﬁcation. We noted a mild rescue effect
without addition of dexamethasone, suggesting that the system is
somewhat leaky. We also examined whether the mutations found in
rfx6 in Mitchell–Riley patients were functional in vivo by testing the
ability of three of the four homozygous mutations to rescue the
morpholino phenotype. We found that none of these mutant
constructs (R181Q, S217P and the exon 7 truncation) were sufﬁcient
to attenuate Rfx6 function in vivo (Fig. 5). This strongly suggests that
mutated rfx6 is responsible for at least some of the defects associated
with Mitchell–Riley syndrome.
One of the beneﬁts of using the Xenopus system to examine the
functional relevance of speciﬁc transcription factors in endoderm
organogenesis is the ability to control protein activity using
hormone-inducible chimeric proteins. By employing this technique
we were able to directly ascertain when Rfx6 function is required in
early endoderm development. Speciﬁcally, we showed that Rfx6
could only rescue the knockdown phenotype when activated at
NF25. This is exactly the stage when we ﬁrst see reduced expression
of hnf6 and foxA2. Our results differ from that seen in mice and
zebraﬁsh where Rfx6 was placed downstream of the transcription
factor Neurogenin 3 (Ngn3), which is essential for development of
endocrine cells (Gradwohl et al., 2000). Our results however, place
Rfx6 upstream of Ngn3. We believe that our functional analysis of
Rfx6 is speciﬁcally focused on the early function of Rfx6, while the
mouse and zebraﬁsh studies focused speciﬁcally on its function inendocrine cells. There is evidence supporting both placements of Rfx6.
Positioning rfx6 downstream of ngn3 is supported by the fact that rfx6
was found in Ngn3+ cells in two screens, and that rfx6 is not expressed
in the ngn3 knockoutmouse (Smith et al., 2010; Soyer et al., 2010). The
fact that pdx1 expression is decreased both in our loss-of-function
study and the knockoutmouse suggests that rfx6 lies upstreamof pdx1,
and hence also ngn3. Also supporting this is the fact that hnf6
expression is decreased in our loss-of-function tissue at NF25, and hnf6
has been shown to be upstream of pdx1 and ngn3 (Jacquemin et al.,
2000; Jacquemin et al., 2003). These observations could also be
explained by a dual role for rfx6: an early role in endoderm patterning
and a later role speciﬁc to endocrine cell development andmaturation.
However, in order to better understand the role(s) of Rfx6, direct
downstream targets need to be found. Additionally, a study separating
the early and late functions of Rfx6 would help ascertain which
functions are directly involved in pancreas development and precisely
which missing functions cause the abnormalities seen in Mitchell–
Riley syndrome, where rfx6 is mutated.
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